Latest News about REGN
Recent news which mentions REGN
From Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
From Benzinga
From InvestorPlace
From Benzinga
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
June 13, 2024
From Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
From Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
June 07, 2024
From Motley Fool
What's Going On With FibroGen Stock Tuesday?
June 04, 2024
From Benzinga
3 Stocks to Watch in Active Growth ETF FDG
June 04, 2024
From ETF Trends
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
June 04, 2024
From Benzinga
From Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
June 03, 2024
From Benzinga
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31, 2024
From Benzinga
What's Going On With Biohaven Stock Wednesday?
May 29, 2024
From Benzinga
2 Biotech Stocks to Buy in May
May 25, 2024
From Motley Fool
From Benzinga
From Motley Fool
From InvestorPlace
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
May 17, 2024
From Benzinga
From Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
May 14, 2024
From Benzinga
From InvestorPlace
From InvestorPlace
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.